Family history of diabetes moderates metabolic depression endophenotypes in overweight/obese adults.


Journal

Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331

Informations de publication

Date de publication:
07 2022
Historique:
received: 27 02 2022
revised: 12 05 2022
accepted: 19 05 2022
pubmed: 1 6 2022
medline: 18 6 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Insulin resistance (IR) is linked to depressive disorders, and there is growing evidence that targeting IR may be beneficial in treating them. We examine the association between depressive symptoms and a direct measure of IR, and whether family history of type 2 diabetes (FHx-T2DM) or major depressive disorder (FHx-MDD) moderate this relationship. Cross-sectional data were collected from 96 primarily overweight/obese adults ages 25-50 without diabetes or clinical depression. Multiple regression and correlation analyses were used to assess the association between depressive symptoms and a direct measure of IR (steady-state plasma glucose) as well as moderating effects of FHx-T2DM or FHx-MDD. In the total sample, elevated depressive symptoms were positively associated with IR (p = 0.005). IR was associated with depressive symptoms in subjects with FHx-T2DM (p = 0.002) or FHx-MDD (p = 0.009) whereas BMI was associated with depressive symptoms in subjects without FHx-T2DM (p = 0.049) or FHx-MDD (p = 0.029). The odds of being in the top tertile of IR increased with elevated depressive symptoms alone (OR, 4.22; 95%CI, 1.15 to 17.33), presence of FHx-T2DM alone (OR, 3.42; 95%CI, 1.26 to 10.00), and presence of both FHx-T2DM and elevated depressive symptoms (OR, 10.08; 95%CI, 1.94 to 96.96). Our findings indicate that depressive symptoms are positively associated with a direct measure of IR in overweight/obese individuals without diabetes or clinical depression. This association is moderated by FHx-T2DM. Early identification of groups vulnerable to IR related to depressive symptomatology may be useful for determining personalized interventions that have the potential to reduce morbidity in later years.

Identifiants

pubmed: 35636036
pii: S0022-3956(22)00271-0
doi: 10.1016/j.jpsychires.2022.05.018
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

583-589

Subventions

Organisme : NIA NIH HHS
ID : R01 AG050345
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Auteurs

Stacie L Ong (SL)

Stanford University School of Medicine, Stanford, CA, 94305, USA.

Fahim Abbasi (F)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Kathleen Watson (K)

Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Thalia Robakis (T)

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Alison Myoraku (A)

Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Natalie Rasgon (N)

Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, 94305, USA. Electronic address: nrasgon@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH